The combination of CpG oligodeoxynucleotide and OX40 agonist antibody (CpG + OX40) can activate a potent in-situ vaccine effect in the preclinical A20 B-cell lymphoma model [15–17]. This evidence concerns the gene TNFRSF4 and B-cell non-Hodgkin lymphoma.